HeartBeam (NASDAQ: BEAT) announced that a peer-reviewed article published in JACC: Advances has demonstrated that a risk prediction algorithm incorporating the company's credit card-sized HeartBeam ECG device can accurately identify heart attack risk in patients presenting with chest pain. The proof-of-concept study, which evaluated 184 patients, found that the algorithm achieved an area under the curve (AUC) of 86.5% using a single HeartBeam ECG reading combined with patient risk factors and symptoms. When a personal, symptom-free baseline ECG was available for comparison, the AUC rose to 92.9%.
The company stated that these results support heart attack detection as a future indication for the HeartBeam System and advance its broader clinical program. The HeartBeam device is a cable-free, portable system that collects ECG signals in 3D from three non-coplanar directions and synthesizes them into a 12-lead ECG. This platform technology is designed for use wherever the patient is, enabling physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility.
The study's high AUC values suggest that the HeartBeam System could become a valuable tool for early heart attack detection, potentially reducing delays in diagnosis and treatment. The ability to compare a patient's current ECG with a personal baseline further enhances accuracy, as individual variations can be accounted for. This approach aligns with the growing trend toward personalized medicine and remote patient monitoring.
HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to its technology. The full press release is available at https://ibn.fm/ainxV.
The findings from this study could have significant implications for emergency medicine and cardiac care. Chest pain is one of the most common reasons for emergency department visits, and rapid, accurate identification of heart attack risk is critical. A portable device that can provide reliable risk assessment at the point of care or even in home settings could streamline triage and reduce unnecessary hospitalizations, while ensuring that high-risk patients receive timely intervention.
HeartBeam plans to pursue further clinical studies to validate these results and seek expanded FDA clearance for heart attack detection. The company's technology represents a step forward in making advanced cardiac diagnostics more accessible and convenient, potentially transforming how heart attacks are detected and managed. For more information about HeartBeam and its technology, visit the company's website at https://www.heartbeam.com/indications for cleared indications for use.
